Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (EWTX): 5 pipeline candidates · ~12 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.4 months
D/E 0.05 · 0% dilution
Lead: Phase 2
5 candidates
N/A
0 buys · 11 sells (180d)
A transparent, data-derived signal for Edgewise Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.7B
Cash
$33.2M
Quarterly Burn
$42.5M
Runway
12.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| EDG-003 | Phase 2 |
| EDG-15400 | Phase 2 |
| EDG-5506 | Phase 2 |
| EDG-7500 | Phase 1 |
| Sevasemten | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
215
Total value held
$3.83B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 15,518,492 | $488.8M |
| janus henderson group plc | 11,831,112 | $372.6M |
| ra capital management, l.p. | 10,428,437 | $328.5M |
| perceptive advisors llc | 8,847,948 | $278.7M |
| vanguard capital management llc | 7,576,322 | $238.7M |
| baker bros. advisors lp | 6,575,940 | $207.1M |
| blackrock, inc. | 6,472,991 | $203.9M |
| novo holdings a/s | 5,350,000 | $168.5M |
| driehaus capital management llc | 4,477,942 | $141.1M |
| cormorant asset management, lp | 3,260,000 | $102.7M |
Showing top 10 of 215 institutional holders of Edgewise Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Edgewise Therapeutics, Inc.'s pipeline?
Edgewise Therapeutics, Inc. (EWTX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Edgewise Therapeutics, Inc.'s lead drug candidate?
Edgewise Therapeutics, Inc.'s most advanced tracked candidate is EDG-003 (Phase 2) for Cardiometabolic disease and other disorders.
What is Edgewise Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Edgewise Therapeutics, Inc. has approximately 12.4 months of cash runway.
What is Edgewise Therapeutics, Inc.'s market capitalization?
Edgewise Therapeutics, Inc.'s market capitalization is approximately $3.7B.
Who is the CEO of Edgewise Therapeutics, Inc.?
Dr. Kevin Koch Ph.D. is the chief executive officer of Edgewise Therapeutics, Inc. (EWTX).
Get the full picture on Edgewise Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.